Context Therapeutics

CNTXPhase 2

Context Therapeutics is committed to advancing the treatment of solid tumors through the development of novel T cell engaging bispecific antibody therapies. The company's pipeline features three clinical-stage candidates targeting antigens such as Claudin 6, mesothelin, and Nectin-4, with a Phase 1 study for CT-95 initiated in late 2025. With a seasoned leadership team and a focus on innovative immunotherapeutic solutions, Context aims to improve outcomes in oncology by overcoming limitations of current TCE approaches.

Market Cap

$264.6M

Focus

Small Molecules

CNTX · Stock Price

USD 2.88+0.63 (+28.00%)

Historical price data

AI Company Overview

Technology Platform

Next-generation T cell engager (TCE) platform utilizing engineered bispecific antibodies designed to bind tumor-associated antigens and CD3 on T cells, with features like avidity enhancement, affinity tuning, and pH-dependency to improve selectivity and safety.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
Onapristone ER + Onapristone ER + Anastrozole	Granulosa Cell Ovarian Cancer	Phase 2
Onapristone + Fulvestrant	ER-positive Breast Cancer	Phase 2
Extended-release Onapristone + Anastrozole	Refractory Endometrial Adenocarcinoma	Phase 2
Elacestrant + Onapristone	Breast Cancer	Phase 1/2
Elacestrant + Onapristone	Breast Cancer	Phase 1/2

Opportunities

The company has significant growth opportunities if its next-generation TCE platform validates in the clinic, potentially addressing large, unmet needs in multiple solid tumor types.

Positive early data could lead to lucrative partnership deals with larger pharmaceutical companies or enhance its standalone value.

Risk Factors

Key risks include clinical failure of its novel TCE candidates, intense competition in the bispecific antibody space, the need for substantial additional capital to fund development, and the inherent risks of its strategic pivot to a new technology platform.

Competitive Landscape

Context operates in the highly competitive field of T cell engagers for solid tumors, facing competition from large pharma (Amgen, Regeneron) and biotech peers. Its differentiation strategy relies on specific protein engineering (pH-dependency, avidity tuning) aimed at improving the therapeutic window over earlier-generation TCEs.